Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
CLINICAL RESEARCH
Mendelian randomization identifies the characteristic plasma metabolite profile of meningioma
1
Department of Neurosurgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Fujian, China
2
Department of Medical Imaging, Zhangzhou Affiliated Hospital of Fujian Medical University, Fujian, China
Submission date: 2024-08-14
Final revision date: 2025-06-18
Acceptance date: 2025-06-19
Online publication date: 2025-06-24
Corresponding author
Zhizhou Zhang
Department of Neurosurgery Zhangzhou Affiliated Hospital of Fujian Medical University 363000, Fujian, China
Department of Neurosurgery Zhangzhou Affiliated Hospital of Fujian Medical University 363000, Fujian, China
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Meningioma, a prevalent intracranial tumor, presents diagnostic and therapeutic challenges due to its heterogeneous nature. Metabolic profiling has emerged as a promising approach to elucidate its underlying molecular mechanisms and discover potential biomarkers.
Material and methods:
This study employed bidirectional Mendelian randomization (MR) analysis to investigate the causal relationship between plasma metabolites and meningioma risk. Genetic instruments were used as surrogates for both plasma metabolites and meningioma, allowing MR analysis in both directions to assess the impact of metabolites on meningioma risk and vice versa. This study encompassed data on 1400 plasma metabolites and 314,708 participants (1316 individuals diagnosed with meningioma and 313,392 individuals without meningioma).
Results:
Initially, 46 plasma metabolites/metabolite ratios were found to be associated with meningioma risk (p < 0.05), with 23 associated with a decreased risk and 23 associated with an increased risk of meningioma. Furthermore, the identified relationships between the 46 plasma metabolites/metabolite ratios and meningioma showed no significant horizontal pleiotropy (p > 0.05), suggesting that the results are not influenced by other confounding factors. Reverse MR analysis revealed that meningioma has no significant impact on the levels of 24 plasma metabolites/metabolite ratios, and is unaffected by confounding factors. In addition, the identified plasma metabolites influence the occurrence of meningioma through nine metabolic pathways.
Conclusions:
The findings of this bidirectional MR study indicate that 24 plasma metabolites/metabolite ratios lead to a significantly increased/decreased risk of meningioma, suggesting that the plasma metabolite profile characteristics serve as important serological tools for the early diagnosis of meningioma.
Meningioma, a prevalent intracranial tumor, presents diagnostic and therapeutic challenges due to its heterogeneous nature. Metabolic profiling has emerged as a promising approach to elucidate its underlying molecular mechanisms and discover potential biomarkers.
Material and methods:
This study employed bidirectional Mendelian randomization (MR) analysis to investigate the causal relationship between plasma metabolites and meningioma risk. Genetic instruments were used as surrogates for both plasma metabolites and meningioma, allowing MR analysis in both directions to assess the impact of metabolites on meningioma risk and vice versa. This study encompassed data on 1400 plasma metabolites and 314,708 participants (1316 individuals diagnosed with meningioma and 313,392 individuals without meningioma).
Results:
Initially, 46 plasma metabolites/metabolite ratios were found to be associated with meningioma risk (p < 0.05), with 23 associated with a decreased risk and 23 associated with an increased risk of meningioma. Furthermore, the identified relationships between the 46 plasma metabolites/metabolite ratios and meningioma showed no significant horizontal pleiotropy (p > 0.05), suggesting that the results are not influenced by other confounding factors. Reverse MR analysis revealed that meningioma has no significant impact on the levels of 24 plasma metabolites/metabolite ratios, and is unaffected by confounding factors. In addition, the identified plasma metabolites influence the occurrence of meningioma through nine metabolic pathways.
Conclusions:
The findings of this bidirectional MR study indicate that 24 plasma metabolites/metabolite ratios lead to a significantly increased/decreased risk of meningioma, suggesting that the plasma metabolite profile characteristics serve as important serological tools for the early diagnosis of meningioma.
REFERENCES (37)
1.
Bhat AR, Wani MA, Kirmani AR, Ramzan AU. Histological-subtypes and anatomical location correlated in meningeal brain tumors (meningiomas). J Neurosci Rural Practice 2014; 5: 244-9.
2.
Huang RY, Bi WL, Griffith B, et al. Imaging and diagnostic advances for intracranial meningiomas. Neurooncology 2019; 21: i44-61.
3.
Lin DD, Lin JL, Deng XY, et al. Trends in intracranial meningioma incidence in the United States, 2004-2015. Cancer Med 2019; 8: 6458-67.
4.
Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neurooncology 2019; 21 (Suppl 5): v1-v100.
5.
Buerki RA, Horbinski CM, Kruser T, Horowitz PM, James CD, Lukas RV. An overview of meningiomas. Future Oncol 2018; 14: 2161-77.
6.
Custer B, Longstreth WT Jr, Phillips LE, Koepsell TD, Van Belle G. Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer 2006; 6: 152.
7.
Phillips LE, Koepsell TD, van Belle G, Kukull WA, Gehrels JA, Longstreth WT Jr. History of head trauma and risk of intracranial meningioma: population-based case-control study. Neurology 2002; 58: 1849-52.
8.
Chen HK, Wu YT, Lin YJ, Lin JW. Clear cell meningioma with frequent chordoid features and aggressive behavior: a clinicopathologic study of ten cases at a single institution. J Neurooncol 2011; 103: 551-9.
9.
Patel B, Desai R, Pugazenthi S, Butt OH, Huang J, Kim AH. Identification and management of aggressive meningiomas. Front Oncol 2022; 12: 851758.
10.
Hui M, Uppin M, Saradhi MV, Sahu B, Purohit A, Sundaram C. Pediatric meningiomas an aggressive subset: a clinicopathological and immunohistochemical study. J Postgrad Med 2015; 61: 32-5.
11.
Yan M, Xu G. Current and future perspectives of functional metabolomics in disease studies – a review. Anal Chim Acta 2018; 1037: 41-54.
12.
Wilkins JM, Trushina E. Application of metabolomics in Alzheimer’s disease. Front Neurol 2018; 8: 323079.
13.
Holeček M. Branched-chain amino acids in health and disease: metabolism, alterations in blood plasma, and as supplements. Nutr Metab 2018; 15: 33.
14.
Arrieta MC, Stiemsma LT, Dimitriu PA, et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci Transl Med 2015; 7: 307ra152.
15.
Clos-Garcia M, Loizaga-Iriarte A, Zuñiga-Garcia P, et al. Metabolic alterations in urine extracellular vesicles are associated to prostate cancer pathogenesis and progression. J Extracell Vesicles 2018; 7: 1470442.
16.
Liu J, Van Klinken JB, Semiz S, et al. A Mendelian randomization study of metabolite profiles, fasting glucose, and type 2 diabetes. Diabetes 2017; 66: 2915-26.
17.
Bull CJ, Bell JA, Murphy N, et al. Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. BMC Med 2020; 18: 396.
18.
Liu X, Tong X, Zou Y, et al. Mendelian randomization analyses support causal relationships between blood metabolites and the gut microbiome. Nat Genet 2022; 54: 52-61.
19.
Jia J, Dou P, Gao M, et al. Assessment of causal direction between gut microbiota–dependent metabolites and cardiometabolic health: a bidirectional Mendelian randomization analysis. Diabetes 2019; 68: 1747-55.
20.
Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. JAMA 2017; 318: 1925-6.
21.
VanderWeele TJ, Tchetgen EJT, Cornelis M, Kraft P. Methodological challenges in mendelian randomization. Epidemiology 2014; 25: 427-35.
22.
He T, Geng X, Lin X, Li Y, Duan Z. Association between gastroesophageal reflux disease and metabolic syndrome: a bidirectional two-sample Mendelian randomization analysis. Arch Med Sci 2024; 20: 1715-9.
23.
Huang Z, He G, Sun S, Feng Y, Huang Y. Causal associations of ambient particulate matter 10 and Alzheimer’s disease: result from a two-sample multivariable Mendelian randomization study. Arch Med Sci 2024; 20: 1604-18.
24.
Huang G, Qian D, Liu Y, Qu G, Qian Y, Pei B. The association between frailty and osteoarthritis based on the NHANES and Mendelian randomization study. Arch Med Sci 2023; 19: 1545-50.
25.
Shen J, Wang Y, Zhou S, et al. Lung function and nonalcoholic fatty liver disease: a Mendelian randomization study. Arch Med Sci 2025; 21: 197-205.
26.
Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genetic Epidemiol 2013; 37: 658-65.
27.
Sekula P, Fabiola Del Greco M, Pattaro C, Köttgen A. Mendelian randomization as an approach to assess causality using observational data. J Am Soc Nephrol 2016; 27: 3253-65.
28.
Chen Y, Lu T, Pettersson-Kymmer U, et al. Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases. Nat Genet 2023; 55: 44-53.
29.
Palmer TM, Lawlor DA, Harbord RM, et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res 2012; 21: 223-42.
30.
Levin MG, Judy R, Gill D, et al. Genetics of height and risk of atrial fibrillation: a Mendelian randomization study. PLoS Med 2020; 17: e1003288.
31.
Gill D, Efstathiadou A, Cawood K, Tzoulaki I, Dehghan A. Education protects against coronary heart disease and stroke independently of cognitive function: evidence from Mendelian randomization. Int J Epidemiol 2019; 48: 1468-77.
32.
Larsson SC, Burgess S, Michaëlsson K. Association of genetic variants related to serum calcium levels with coronary artery disease and myocardial infarction. JAMA 2017; 318: 371-80.
33.
Masalha W, Daka K, Woerner J, et al. Metabolic alterations in meningioma reflect the clinical course. BMC Cancer 2021; 21: 211.
34.
Talari NK, Panigrahi M, Madigubba S, Challa S, Phanithi PB. Altered tryptophan metabolism in human meningioma. J Neurooncol 2016; 130: 69-77.
35.
Petersen G, Moesgaard B, Schmid PC, et al. Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-tumour brain tissue. J Neurochem 2005; 93: 299-309.
36.
Bachir S, Shah S, Shapiro S, et al. Neurofibromatosis type 2 (NF2) and the implications for vestibular schwannoma and meningioma pathogenesis. Int J Mol Sci 2021; 22: 690.
37.
Oyem PC, de Andrade EJ, Soni P, et al. Natural history and volumetric analysis of meningiomas in neurofibromatosis type 2. Neurosurg Focus 2022; 52: E5.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
